✦ LIBER ✦

Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST

✍ Scribed by Vincenzo Pitini; Carmela Arrigo; Maria Grazia Sauta; Giuseppe Altavilla

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 924 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2009.04.012

No coin nor oath required. For personal study only.

✦ Synopsis

The introduction of imatinib has been a major advance in the treatment of gastrointestinal stromal tumor (GIST). However, despite its remarkable efficacy and toxicity profile little is known about the potential for long-term toxicity. This may be an important issue because some patients (pts) with chronic myelogenous leukemia (CML) develop, during imatinib treatment, chromosomal abnormalities in philadelphia chromosome (Ph) negative cells with evolution to myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), furthermore a nonrandom association between GIST and myeloid leukemia has been recently reported. We report here a case of refractory cytopenia with mutilineage dysplasia (RAEB-1) with monosomy 7 which rapidly transformed into AML in a patient with GIST during imatinib treatment.

📜 SIMILAR VOLUMES

Surgical treatment of patients with init

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

✍ Piotr Rutkowski; Zbigniew Nowecki; Pawel Nyckowski; Wirginiusz Dziewirski; Urszu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB

Results of imatinib mesylate therapy in

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated

Secondary myelodysplastic syndrome in a

Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate

✍ Arturo Vega-Ruiz; Susan O’Brien; Jorge Cortes; Partow Kebriaei; Deborah Thomas; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 90 KB

The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in c

The significance of myelosuppression dur

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade 3, requiring interruption of thera

Chromosomal abnormalities in Philadelphi

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

✍ Jorge Medina; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Ma 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract ## BACKGROUND Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome (Ph)‐negative metaphases have been reported in patients with chronic myelogenous leukemia (CML) in the chronic phase during treatment with interferon and, more recently, with imatinib. This phenomenon

P107 Chromosomal abnormalities in Philad

P107 Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase

✍ S. Jootar 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 51 KB

6/155), high white cell number (13/155) (red cell unit) or low thrombocyte number (14/125) (thrombocyte unit). Summary: Donors with low hemoglobin levels have to be excluded from the blood donation service for 3 months. So, in theory haemoglobin concentration of all total blood units is suitable for